FY2025 EPS Estimates for Pfizer Inc. Increased by Leerink Partnrs (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Leerink Partnrs boosted their FY2025 EPS estimates for shares of Pfizer in a research note issued to investors on Thursday, May 2nd. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will earn $2.93 per share for the year, up from their prior estimate of $2.68. The consensus estimate for Pfizer’s current full-year earnings is $2.36 per share. Leerink Partnrs also issued estimates for Pfizer’s FY2028 earnings at $2.69 EPS.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the prior year, the firm posted $1.23 earnings per share. Pfizer’s revenue for the quarter was down 19.5% compared to the same quarter last year.

PFE has been the topic of a number of other reports. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday. Finally, Morgan Stanley upped their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $36.00.

Pfizer Stock Performance

Pfizer stock opened at $27.81 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer has a 12 month low of $25.20 and a 12 month high of $40.37. The company has a fifty day moving average price of $26.88 and a two-hundred day moving average price of $28.21. The company has a market cap of $157.48 billion, a PE ratio of -463.42, a P/E/G ratio of 1.18 and a beta of 0.63.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.04%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its position in shares of Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after acquiring an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC acquired a new position in shares of Pfizer in the 4th quarter worth $255,000. ETF Store Inc. raised its position in shares of Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 727 shares during the period. KLCM Advisors Inc. lifted its holdings in shares of Pfizer by 75.0% during the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after purchasing an additional 74,487 shares during the last quarter. Finally, Farmers Trust Co. boosted its position in shares of Pfizer by 2.0% in the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock valued at $6,503,000 after purchasing an additional 4,410 shares during the period. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.